2021

  • ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED) on May 10, 2021, Application No.3,033,046. 

  • ALA-1000 Receive notice of patent allowance from the IP New Zealand on April 30, 2021. Patent No. 750367

  • ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office on April 16, 2021 (Application No. 10-2019-7009185). 

  • ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) on April 12, 2021 (Application No. 2019102895). 

2020

  • Listed on Taipei Exchange Market in Taiwan on 23 September ,Traded on October 5
  • ALA-1000 Receive notice of patent allowance from the IP Australia.
  • ALA-3000 completes Pre-IND Meeting with US FDA
  • ALA-1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI)
  • Approved to be a public offering company on June 3.  Code : ( 6785 )
  • Receive notice of patent allowance from USPTO ( ALA-1000)
  • ALA-1000 was approved by  Ministry of Economic Affairs : A+ Industrial Innovation R&D Program(fast track)

2019

  • Approved by the Ministry of Economic Affairs as a Biotech Pharmaceutical  company

  • ALA-1000  received US FDA IND approval.

  • Approved to locate in Central Science Park

2017

  • ALA-1000 was approved by Ministry of Economic Affairs :A+ Industrial Innovation R&D Program-Industrial Technology Foresight Research Program

2016

  • Alar Pharmaceuticals Inc was founded